Abbott Dumps Generic Drugs Business, Looks For More Device Targets
This article was originally published in The Gray Sheet
Executive Summary
Mylan will buy Abbott’s non-U.S. developed markets specialty and branded generics business in a stock transaction valued at around $5.3 billion, a deal that will allow it to redomicile in the Netherlands.